Figure 6.
Figure 6. Leukapheresis and cryopreservation of CACs and EPCs. (A) The efficiency of leukapheresis of CACs and EPCs was estimated as described in “Materials and methods” and compared with the efficiency of CD34 harvest (set at 100%). (B) CACs were harvested from cultures of pheresis MNCs, and 400 000 were transplanted into NOD/SCID β2M mice 24 hours after induction of hind-limb ischemia (AMD3100, n = 6; G-CSF, n = 5; control, n = 10) (*P < .01, **P < .05). (C) The number of CACs and EPCs from the cryopreserved pheresis product was quantified and compared with the corresponding fresh pheresis product (n = 4). (D) A total of 400 000 CAC-harvested cultures of cyropreserved pheresis MNCs (Cryo CAC) were transplanted into NOD/SCID β2M mice 24 hours after induction of hind-limb ischemia (cryopreserved, n = 5; control, n = 10). ***P < .001. Data represent mean ± SEM.

Leukapheresis and cryopreservation of CACs and EPCs. (A) The efficiency of leukapheresis of CACs and EPCs was estimated as described in “Materials and methods” and compared with the efficiency of CD34 harvest (set at 100%). (B) CACs were harvested from cultures of pheresis MNCs, and 400 000 were transplanted into NOD/SCID β2M mice 24 hours after induction of hind-limb ischemia (AMD3100, n = 6; G-CSF, n = 5; control, n = 10) (*P < .01, **P < .05). (C) The number of CACs and EPCs from the cryopreserved pheresis product was quantified and compared with the corresponding fresh pheresis product (n = 4). (D) A total of 400 000 CAC-harvested cultures of cyropreserved pheresis MNCs (Cryo CAC) were transplanted into NOD/SCID β2M mice 24 hours after induction of hind-limb ischemia (cryopreserved, n = 5; control, n = 10). ***P < .001. Data represent mean ± SEM.

Close Modal

or Create an Account

Close Modal
Close Modal